Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pharmacists on the front line: a new strategy to fight heart disease in people with HIV

NCT ID NCT07711366

Disease control Sponsor: Temple University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

People living with HIV have twice the risk of heart attacks and stroke compared to the general population. This trial tests whether integrating clinical pharmacists into HIV care can improve blood pressure control and reduce cardiovascular disease risk. The study enrolls 450 adults with HIV and high blood pressure in Kenya, and the pharmacist-led program includes medication management, access to heart medicines, and peer support. Researchers will measure changes in blood pressure, medication adherence, and quality of life over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a pharmacist-led care program that includes medication management, access to heart medicines, and peer support
What this could lead to
If effective, this approach could provide a scalable way to lower heart attack and stroke risk in people living with HIV, especially in regions with limited healthcare resources.
What could go wrong
This is a relatively early-stage implementation study with 450 participants, so results may not apply broadly. The intervention depends on local health systems and pharmacist availability, which may limit reproducibility.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients 18 years or above * Actively enrolled in the AMPATH HIV care program * Screen positive for and confirmed to have hypertension through repeated blood pressure measurement (SBP ≥ 140 or diastolic BP (DBP) ≥ 90), or those who are already in care for hypertension Exclusion Criteria: * Hypertensive emergency requiring immediate medical attention * Terminal illness * Pregnancy * Inability to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease prevention are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder HIV infectious disease hypertensive disorder Medication Adherence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular disease prevention HIV Hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kitale County Referral Hospital

    Kitale, Trans Nzoia County, Kenya

  • Moi Teaching and Referral Hospital

    Eldoret, Uasin Gishu County, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.